Neuromyelitis optica (NMO) and multiple sclerosis (MS) are both autoimmune inflammatory and demyelinating disorders of the central nervous system. Recently, more than 50 MS-susceptibility single-nucleotide polymorphisms (SNPs) have been detected outside the major histocompatibility complex (MHC) region. In this study, we aimed to evaluate the association of these identified non-MHC MS risk loci with Chinese patients with NMO. Thirtyfive non-MHC SNPs were selected and genotyped by matrix-assisted laser desorption/ionization timeof-fl ight mass spectrometry (MALDI-TOF MS) in 110 NMO patients and 332 controls from southeastern China. Among the 35 SNPs, only one, rs1800693 in the TNFRSF1A locus, was nominally associated with NMO (P = 0.045, OR = 1.550, 95% CI = 1.007 -2.384). However, none of the 35 SNPs was associated with NMO after Bonferroni correction. Our results showed no association between these identified non-MHC MS risk loci and NMO, suggesting there are genetic differences in the etiology of NMO and MS.
INTRODUCTION
Neuromyelitis optica (NMO) and multiple sclerosis (MS) are both autoimmune inflammatory demyelinating disorders of the central nervous system. Although NMO was once considered to be a variant of MS, it is now deemed distinct from MS because of the detection of NMO immunoglobulin G (NMO-IgG), an autoantibody against aquaporin 4 (AQP4) [1] .
The prevalence of NMO is ~1 per 100,000 [2, 3] . Interestingly, NMO is relatively common in Asian populations but rare in Caucasians [4] .
The genetic component of MS is complex and has been studied for decades. For over 30 years, the major histocompatibility complex (MHC) was the only known MS susceptibility locus. However, recent genomewide association studies have revealed that >50 single nucleotide polymorphisms (SNPs) outside the MHC region are closely associated with susceptibility to MS [5] [6] [7] [8] [9] [10] [11] [12] .
Although the genetic susceptibility of NMO remains largely unknown because of the limited number of cases, reports of familial aggregation have provided strong evidence that genetic factors influence the susceptibility to NMO seemingly similar to MS [13, 14] . However, to date, whether the MS non-MHC risk loci are also associated with NMO has rarely been investigated. In this study, we recruited 110 NMO cases and evaluated whether these non-MHC MS risk SNPs were also associated with Chinese NMO patients.
METHODS

Participants
A total of 110 unrelated NMO patients (21 males, 89 [16] . Written informed consent was given by participants >18 years of age and guardians on the behalf of those <18 years old prior to inclusion. This study was approved by the Ethics Committee of Huashan Hospital.
Anti-AQP4 antibodies were detected with an indirect immunofluorescence assay using HEK293 cells transfected with the recombinant human AQP4 gene (Euroimmun, Lubeck, Germany) [17] . Each sample was measured at least twice, with the examiners blind to the origin of the specimens. Samples with a positive result twice were considered to be positive for anti-AQP4 antibody.
Genotyping
Genomic DNA was extracted from peripheral EDTA blood using a TIANamp Blood DNA kit (Tiangen Biotech, Beijing). The resulting products were desalted and transferred to a 384-element SpectroCHIP array (Sequenom). Alleles were detected using a matrix-assisted laser desorption/ionization time-of-fl ight mass spectrometry (MALDI-TOF MS) platform (MassArray TM, Sequenom) according to a previously described method [18] .
Statistical Analyses
Hardy-Weinberg equilibrium was tested using the χ 2 test. 
RESULTS
Overall, 4 NMO patients and 28 controls who had a SNP genotyping success rate <90% were excluded, so a total of 106 NMO patients and 304 controls were analyzed. Their demographic and clinical characteristics are listed in Table   2 . Anti-AQP4 antibodies were tested in 77 of 106 NMO patients and 44 (57.14%) were positive, which is lower than that in the previous study [1] . In addition, complete cerebrospinal fl uid analysis at disease onset was available for 67 NMO patients and the oligoclonal-band-positive rate was 10/67 (14.93%).
The average genotyping success rate across the SNPs was 99.5%. All SNPs were in Hardy-Weinberg equilibrium (Table 1 ). The association testing of 35 SNPs with NMO is shown in Table 3 . Among these, only one SNP, rs1800693
in the TNFRSF1A locus, was nominally associated with NMO (P = 0.045, OR = 1.550, 95% CI = 1.007-2.384). In addition, none of these SNPs was associated with NMO after Bonferroni correction. In further analysis, based on the anti-AQP4 antibody status, there was no significant difference in the allele frequencies in the 35 selected SNPs between the anti-AQP4-positive and negative NMO patients (Table 4) .
DISCUSSION
In clinical practice, it is difficult to differentiate NMO from MS due to an overlap of manifestations, such as optic neuritis, spinal syndrome, and female predilection. Since the discovery of NMO-IgG, the discrimination of NMO from Among the genes that have been implicated in MS susceptibility, the greatest individual impact is from the human leukocyte antigen (HLA) locus. The HLA DRB1*1501 allele is consistently associated with MS in most Europeans, African Americans, and Japanese [19] [20] [21] . In contrast, early studies of Japanese populations suggested some association of optic-spinal MS susceptibility with the DPB1*0501 allele, which was different from that in MS [22] . After the discovery of anti-AQP4 antibody, the DPB1*0501 allele was also reported to be associated with NMO in Japanese and southern Han Chinese, while the DRB1*03 allele was reported to be a risk factor for NMO in Caucasians, suggesting differences in genetic background [23] [24] [25] . Furthermore, the DPB1*0501 allele is a risk factor for anti-AQP4-positive NMO, but not for anti-AQP-negative NMO [26] . However, to date, no specific CYP7A1 that encodes cytochrome P450 has a protective role in the risk of NMO [27] , which was replicated in our previous study [16] . Also, the allele of programmed death-1 was found to be associated with NMO [28] . However, a genetic analysis of AQP-4 in NMO indicated no association of AQP-4 variation with susceptibility to NMO [29] . No genetic variant of OPAI, the major causative gene for autosomal dominant optic atrophy, has been associated with NMO [30] .
Thus, the genetics of NMO is still largely unknown and more studies are required to reveal it.
To date, little is known about the genetic differences between NMO and MS apart from the HLA locus. In the current study, we fi rst evaluated the association of 35 non-MHC MS-susceptibility loci with Chinese NMO patients and found that none of them was associated with NMO.
Moreover, there was no difference in the allele frequencies of the 35 selected SNPs between the anti-AQP4 positive and negative NMO patients, which indicated that these non-MHC loci are not associated with anti-AQP4 antibody status. Therefore, it is conceivable that NMO differs from MS regarding genetic susceptibility, irrespective of MHC or non-MHC loci, and the development of AQP4 autoimmunity is attributable to a certain genetic background and is mainly mediated by MHC loci.
In summary, our fi ndings provide further evidence for genetic differences between NMO and MS, suggesting two distinct disease entities. However, these data are preliminary and need to be further replicated in a larger cohort. [5] [6] [7] [8] [9] [10] [11] [12] . CI, confi dence interval; Negative, NMO negative for anti-AQP4 antibody; NMO, neuromyelitis optica; OR, odds ratio; Positive, NMO positive for anti-AQP4 antibody; RAF, risk allele frequency. a The risk alleles are based on the referenced study [5] [6] [7] [8] [9] [10] [11] [12] .
